RFA-HL-26-020 Catalyze R33 eligibility Guide
Updated 8 official sources
Quick Answer: RFA-HL-26-020 is the NHLBI Catalyze direct-to-R33 route for medical device prototype optimization tied to heart, lung, blood, and sleep diseases and disorders.
Full answer and how we checked it
It is clinical trial not allowed and fits teams ready to optimize, test, and de-risk a device prototype. The October 21, 2026 date has passed; the next due date is February 11, 2027, followed by June 17 and October 21, 2027, with a $300,000 direct-cost-per-year cap, a 2-year maximum project period, and an expected non-federal cash match.
Who this is for: Biomedical device teams, translational researchers, small companies, university labs, technology transfer offices, and sponsored-research teams deciding whether Catalyze R33 is the right product-definition route.
Data note: This guide uses NIH RFA-HL-26-020, the NHLBI Catalyze FAQ, Grants.gov listing 357340, NIH RePORTER award records pulled on October 6, 2026, and Grantsights award-data signals, with the RFA's dates, funding plan, and required attachments checked on October 1, 2026.
In this guide
- Source Check
- 7 RFA-HL-26-020 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- Who the Device R33 Has Funded: 6 Projects in NIH RePORTER
- What NHLBI Doesn't Tell You
- 2 Missing Documents That Stop Review
- What "Ready for Prototype Optimization" Means in the NOFO
- Milestones Are Reviewed, Negotiated, and Enforced
- 6 Evidence Assets That Make This R33 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day Catalyze R33 Readiness Plan
- 6 Final Research Checks Before Submission
- 4 Decision Questions Before You Draft
- 3 Last-Mile Checks For Device Teams
- 7 Catalyze R33 Checks Before February 11, 2027
- Sources
According to NIH in RFA-HL-26-020 (opens in a new tab), this Catalyze Product Definition NOFO provides early-stage translational support for prototype testing and design modification, diagnostic disease target assay development, and research tools for heart, lung, blood, and sleep diseases and disorders.
The decision question is whether the team has a device prototype that is ready for optimization and milestone-driven translational work, or whether the project is still earlier target discovery, first prototype design, or clinical testing.
Use this guide with the live NHLBI Catalyze R33 medical device program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI Clinical Trial Pilot R34 guide, NHLBI Emerging Investigator Award R35 guide, BIG S10 guide, NIH SBIR and STTR guide, NHLBI payline guide, and the Grantsights grant database.
Source Check
Checked October 2026.
As of October 24, 2026, RFA-HL-26-020 (opens in a new tab) remains open. The October 21, 2026 date has passed, and 3 due dates are left: February 11, 2027, June 17, 2027, and October 21, 2027, with expiration on December 24, 2027. Note that the June 2027 date is June 17, not June 18. For the October 21, 2026 date that just closed, NIH lists March 2027 review, May 2027 council, and a July 2027 earliest start. The January 28, 2026 NIH notice removed AIDS application due dates from this NOFO, so do not rely on older AIDS-date summaries.
The source screen also needs 3 product-readiness gates. NIH expects prototype testing or design modification, not early target discovery or clinical research. NHLBI requires at least one Accelerator Partner. Cost matching is expected, with a recommended minimum 0.25:1 non-federal cash match of requested federal direct costs.
The pool is small and shared. NHLBI says it intends to commit up to $4,466,000 in total costs in each of FY2026, FY2027, and FY2028 and to fund up to 8 new awards a year. That ceiling covers this NOFO and its 3 Catalyze companions, RFA-HL-26-017, RFA-HL-26-018, and RFA-HL-26-019, for up to 24 new awards in all.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
7 RFA-HL-26-020 Eligibility Stop Checks
| Stop check | Strong Catalyze R33 signal | Red flag |
|---|---|---|
| Mission fit | Heart, lung, blood, or sleep need is direct | General device platform |
| Stage | Prototype optimization is ready | Early concept only |
| Trial status | No clinical trial proposed | Human trial needed |
| Milestones | Go/no-go milestones are measurable | Open-ended R&D |
| Product path | Design inputs and testing plan are clear | Academic aims only |
| Team | Device, regulatory, and translational roles exist | Missing product skill |
| Route fit | Prototype stage fits this R33 | Earlier device work belongs in RFA-HL-26-016 |
Device teams can miss this route by being either too early or too clinical.
5 Source Facts Applicants Should Know
NIH identifies the route as RFA-HL-26-020, Catalyze Product Definition: Medical Device Prototype Optimization, R33 clinical trial not allowed. NIH lists due dates through October 21, 2027 and an expiration date of December 24, 2027.
According to NIH RFA-HL-26-020 (opens in a new tab) and the NHLBI Catalyze FAQ (opens in a new tab), this opportunity is direct to R33 and budgets must not exceed $300,000 in direct costs per year.
| Fact | Source-backed read |
|---|---|
| Funding number | RFA-HL-26-020 |
| Mechanism | R33 direct-to-award route |
| Clinical trial status | Not allowed |
| Budget cap | $300,000 direct costs per year |
| Next due date | February 11, 2027 |
| Project period | 2 years maximum |
| Later due dates | June 17 and October 21, 2027 |
| Match signal | 0.25:1 non-federal cash match recommended |
Who the Device R33 Has Funded: 6 Projects in NIH RePORTER
Grantsights checked RFA-HL-26-020 and the notices it replaced against NIH RePORTER award records on October 6, 2026. NIH lists RFA-HL-26-020 as a reissue of RFA-HL-23-014 (opens in a new tab), which reissued RFA-HL-20-028 (opens in a new tab). A search of the NIH RePORTER project API (opens in a new tab) by those 3 funding opportunity numbers returned 6 new R33 projects: 3 under RFA-HL-23-014 in FY2023 through FY2025 and 3 under RFA-HL-26-020 in FY2026. It returned no awards under RFA-HL-20-028.
| Fiscal year | Recipient | State | Notice | Project | First-year total costs |
|---|---|---|---|---|---|
| 2023 | University of Cincinnati | OH | RFA-HL-23-014 | Vortical airflow for CPAP without a tight seal | $401,849 |
| 2024 | University of Vermont | VT | RFA-HL-23-014 | Pleural and tracheal sealant | $381,000 |
| 2025 | University of Pittsburgh | PA | RFA-HL-23-014 | Manufacturability of tissue-engineered vascular grafts | $344,056 |
| 2026 | VenoStent, Inc. (opens in a new tab) | TX | RFA-HL-26-020 | Bioabsorbable perivascular wrap for fistula surgery | $404,385 |
| 2026 | University of North Carolina at Chapel Hill (opens in a new tab) | NC | RFA-HL-26-020 | Assay for hyperfibrinolysis in trauma | $445,748 |
| 2026 | University of Vermont (opens in a new tab) | VT | RFA-HL-26-020 | Pleural and tracheal sealant, continued | $450,096 |
Grantsights analysis of these NIH RePORTER records shows 4 things the RFA text doesn't.
- Money arrives a year at a time. Each FY2026 award's first budget period ends May 31, 2027, and each RFA-HL-23-014 project has a separate second-year record. Across both years, those 3 earlier projects received $636,945 to $748,000 in total costs. That matches the NOFO's rule that continuation depends on meeting milestones.
- The federal award is only part of the budget. Specifically, VenoStent, Inc. received $404,385 in first-year total costs for its perivascular wrap. RePORTER amounts are NIH funds only, so the expected 0.25:1 non-federal cash match comes on top of figures like these.
- Companies win here, and so do returning teams. VenoStent, a Houston company, won 1 of the 3 FY2026 awards. The University of Vermont's sealant project was funded under RFA-HL-23-014 in FY2024 and FY2025, then won a new RFA-HL-26-020 award in FY2026 under the same project title, so a strong first R33 can lead to a second.
- This notice took 3 of 10 awards from a shared pool in FY2026. NHLBI planned up to 8 new awards a year across this notice and RFA-HL-26-017, RFA-HL-26-018, and RFA-HL-26-019. According to NIH RePORTER, FY2026 brought 10 new awards across those 4 notices: 4 under RFA-HL-26-017, 3 under RFA-HL-26-019, 3 under this notice, and none under RFA-HL-26-018, which shows 1 renewal. Companies took 5 of the 10.
A company deciding between this R33 and small-business funding can compare the NIH SBIR and STTR guide with the SBIR Phase I guide before choosing; RFA-HL-26-020 accepts both universities and for-profit organizations.
What NHLBI Doesn't Tell You
Within 21 days, answer 4 practical questions. First, prototype optimization is a specific stage. A team should already know the disease target, intended use, user, device concept, and key design risks.
Second, the Catalyze structure expects milestone discipline. For example, a company building a sleep-disorder wearable should not submit a broad product roadmap. It should define optimization tests, acceptance criteria, regulatory assumptions, and the next funding or development step.
Third, no clinical trial means no clinical trial. Don't design the project around prospective human efficacy testing and try to call it engineering.
Fourth, product teams need product evidence. A strong application reads less like an R01 and more like a translational development plan.
2 Missing Documents That Stop Review
RFA-HL-26-020 has two items that NIH treats as completeness checks. Leave either out and the application is not peer-reviewed.
| Required item | What it must contain |
|---|---|
| Accelerator Partner letter of support | Evidence of at least one commercialization partner; the NOFO says a partner may also supply the match but does not have to |
| IP and Regulatory Strategies.pdf | Known IP constraints, prior filings and publications, competing patented or marketed products, any third-party IP needed, and the regulatory path |
The regulatory section is more specific than most teams expect. For a device or diagnostic, NIH asks applicants to describe the data the project will collect to support an FDA pre-submission meeting, a 510(k), or an Investigational Device Exemption filing. A project too early for a defined strategy should say so and describe its current stage.
Three budget rules belong in the same pass. The total project budget justification must show the federal request and the non-federal match separately, and the match must be documented before NIH releases the award. Each budget year should include travel for the PD/PI to a 1.5-day NHLBI innovation meeting or workshop in the Washington, DC area. Any non-federal source of matching funds needs its own letter of support.
What "Ready for Prototype Optimization" Means in the NOFO
NIH lists the work a device team is expected to have finished before applying. That list is the clearest stage test on the page:
- Key components tested, such as electronics, control and feedback systems, sensing elements, stent deployment, or fluid handling
- Computational modeling used to inform design features
- A first prototype or bench-top unit, assessed for anatomical fit and ease of implantation
- In vitro testing, acute in vivo testing, and small-animal testing
- Limited biocompatibility, hemocompatibility, and histopathology testing
A team that has not built a first prototype is outside this NOFO. NIH points early device and diagnostic work, including initial prototypes and diagnostic target identification, to the companion RFA-HL-26-016. It sends therapeutic agent development to RFA-HL-26-017 and RFA-HL-26-018. Biomarker development and clinical research are not responsive to this NOFO.
Milestones Are Reviewed, Negotiated, and Enforced
Catalyze milestones carry more weight than in a standard R-series grant. NIH says milestones must be specific, measurable, achievable, relevant, and time-bound, that each Specific Aim needs at least one, and that a list of aims or activities does not count as milestones. The timeline with milestones must be the last element of the Research Strategy.
After review, NHLBI may negotiate the milestones before they become award terms. Program staff then hold quarterly meetings and make each non-competing continuation decision based on whether milestones were met. These awards also do not get the automatic one-time no-cost extension, so every extension needs prior NIH approval. Reviewers are told to judge whether milestones are measurable, whether timelines are realistic and non-duplicative, and whether the project management structure can keep the work on schedule.
6 Evidence Assets That Make This R33 Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the HLBS fit memo. State the disease, user, unmet need, and why NHLBI is the right home.
Asset 2 is the prototype status memo. Include drawings, design inputs, prior tests, known failure modes, and optimization questions.
Asset 3 is the milestone table. Each milestone should have a test, threshold, decision, and next action.
Asset 4 is the regulatory and quality memo. Include intended use, risk class hypothesis, standards, testing, and documentation gaps.
Asset 5 is the team table. Include engineering, clinical, regulatory, product, statistics, and commercialization roles.
Asset 6 is the route comparison. Compare RFA-HL-26-020 with RFA-HL-26-016 for earlier device work, SBIR/STTR, NHLBI R34, and private translational funds.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| RFA-HL-26-020 | Prototype optimization is ready | Route fits |
| RFA-HL-26-016 | Initial prototype or diagnostic target work is needed | NIH routes early device work there |
| SBIR/STTR | Company-led product path is central | Small-business route may fit |
| NHLBI R34 | Clinical trial planning is next | Pilot route may fit |
| Private capital | Product risk is market not science | Non-grant path may fit |
The strongest applications can explain why the device is beyond discovery but not yet in clinical testing.
6 Bad-Fit Signals
First, HLBS mission fit is weak. Second, the project is still target discovery. Third, no working prototype exists.
Fourth, the project requires a clinical trial. Fifth, milestones are vague. Sixth, the team lacks device-development or regulatory skill.
If any of these apply, settle the route first: device teams need a clear route decision before they spend months on an application.
21-Day Catalyze R33 Readiness Plan
Days 1 through 3 should confirm deadline, clinical-trial status, HLBS fit, and device stage. Days 4 through 7 should build the prototype status memo.
Days 8 through 12 should write milestones, acceptance criteria, and testing design. Days 13 through 16 should review regulatory and quality assumptions. Days 17 through 21 should compare Catalyze R33, earlier Catalyze paths, SBIR/STTR, R34, and private funding.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final research checks. Check 1 is the NIH RFA. Check 2 is the Catalyze FAQ budget table. Check 3 is no-trial status. Check 4 is device stage. Check 5 is milestone measurability. Check 6 is whether the team should use SBIR/STTR instead.
You're ready when the team can describe the product risk that R33 funding will reduce and what happens if each milestone passes or fails.
4 Decision Questions Before You Draft
Within 21 days, ask 4 public decision questions. Question 1: "Is the device already past first prototype design?" Question 2: "Is the disease area heart, lung, blood, or sleep?" Question 3: "Can the team name measurable optimization milestones?" Question 4: "Would a clinical trial be needed to prove the next claim?"
If the fourth answer is yes, RFA-HL-26-020 is probably not the right next step. If the first answer is no, the NOFO points early device work to RFA-HL-26-016.
3 Last-Mile Checks For Device Teams
Within 21 days, run 3 last-mile checks before submitting. Check 1 is the milestone budget match: every major cost should support a named optimization test or product-definition decision. Check 2 is evidence continuity: prior prototype data, new testing, and the next development step should read as one path. Check 3 is evidence clarity: the team should be able to say what evidence the R33 will create for NHLBI, investors, partners, or a later clinical-study route.
If those 3 checks are weak, the application may look like general product spending instead of Catalyze-ready translational work.
7 Catalyze R33 Checks Before February 11, 2027
The October 21, 2026 date has passed; the next due date is February 11, 2027, with 2 more later in 2027. Run these 7 checks before choosing a date. Each row comes from RFA-HL-26-020 (opens in a new tab) or from the RePORTER check above.
| Check | What to confirm | Where it comes from |
|---|---|---|
| Stage | A first prototype exists, with bench, in vitro, or small-animal test data | RFA-HL-26-020 readiness list |
| Mission | The device targets a heart, lung, blood, or sleep disease or disorder | RFA-HL-26-020 |
| Partner | A letter of support from at least 1 Accelerator Partner | RFA-HL-26-020 completeness check |
| Match | A 0.25:1 non-federal cash match of federal direct costs, documented before award | RFA-HL-26-020 cost matching |
| Budget | No more than $300,000 in direct costs a year, for up to 2 years | RFA-HL-26-020 award budget |
| Award size | First-year total costs of $404,385 to $450,096 on the 3 FY2026 awards | NIH RePORTER, October 6, 2026 |
| Next action | Apply on February 11, 2027, wait for a later 2027 date, or move earlier work to RFA-HL-26-016 | Route table above |
Sources
- NIH RFA-HL-26-020 (opens in a new tab)
- NHLBI Catalyze product-definition FAQ (opens in a new tab)
- Grants.gov listing 357340 (opens in a new tab)
- NIH RFA-HL-23-014, the previous device R33 notice (opens in a new tab)
- NIH RePORTER project search API (opens in a new tab), queried October 6, 2026 for RFA-HL-20-028, RFA-HL-23-014, and RFA-HL-26-016 through RFA-HL-26-020
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the R33 record
Check RFA-HL-26-020, prototype stage, no-trial status, $300,000 cap, and match.
Compare NHLBI R34
Use when the device is moving toward clinical-trial planning instead of prototype optimization.
Compare SBIR/STTR
Use when the product path is company-led and small-business eligibility controls the route.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does RFA-HL-26-020 fund?
It funds NHLBI Catalyze R33 medical device prototype optimization for heart, lung, blood, and sleep diseases and disorders.
Are clinical trials allowed?
No. RFA-HL-26-020 is clinical trial not allowed.
What budget cap applies?
NIH and the Catalyze FAQ state that application budgets must not exceed $300,000 in direct costs per year for this opportunity.
What stage fits?
A device should be ready for prototype optimization, not only early concept discovery.
Who should skip this route?
Skip it if the device lacks HLBS mission fit, needs a clinical trial, or is still at target discovery or first prototype design.
Last updated October 24, 2026. Corrected October 24, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NHLBI R61/R33 Early Phase Eligibility Guide
NHLBI R61/R33 guide: 8 checks for PAR-25-026, Phase 0/I trials, HLBS fit, $250K R61 cap, $1.515M R33 cap, and milestones.
Help With Medical Bills 2026: Charity Care and Your Rights
No government grants pay medical bills, but nonprofit hospitals must give you 240 days to apply for financial aid. Your rights and the real help.
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.